Aurobindo Pharma Q2FY17

1. Consolidated Net Profit Up 33.5% At Rs 605.6 cr v/s Rs 453.5 cr (YoY) 
2. Consolidated Total Income Up 12.2% At Rs 3,775.4 cr v/s Rs 3,365.1 cr (YoY) 
3. Consolidated EBITDA Up 19.3% At Rs 929.20 cr v/s Rs 779 cr (YoY) 
4. Consolidated EBITDA Margin At 24.6% v/s 23.1% (YoY)